221 related articles for article (PubMed ID: 36003398)
1. Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome.
Attrill GH; Lee H; Tasker AT; Adegoke NA; Ferguson AL; da Silva IP; Saw RPM; Thompson JF; Palendira U; Long GV; Ferguson PM; Scolyer RA; Wilmott JS
Front Immunol; 2022; 13():979993. PubMed ID: 36003398
[TBL] [Abstract][Full Text] [Related]
2. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
[TBL] [Abstract][Full Text] [Related]
3. Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients.
De Logu F; Galli F; Nassini R; Ugolini F; Simi S; Cossa M; Miracco C; Gianatti A; De Giorgi V; Rulli E; Cossu A; Massi D; Mandalà M
Cells; 2021 Feb; 10(2):. PubMed ID: 33671367
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials.
Edwards J; Tasker A; Pires da Silva I; Quek C; Batten M; Ferguson A; Allen R; Allanson B; Saw RPM; Thompson JF; Menzies AM; Palendira U; Wilmott JS; Long GV; Scolyer RA
Clin Cancer Res; 2019 Jun; 25(11):3247-3258. PubMed ID: 30777877
[TBL] [Abstract][Full Text] [Related]
6. Location of CD39
Koppensteiner L; Mathieson L; Pattle S; Dorward DA; O'Connor R; Akram AR
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648263
[TBL] [Abstract][Full Text] [Related]
7. Immune profiling identifies CD8
Chen Z; Guo ML; Li YY; Yan K; Li L; Shen F; Guan H; Liu QZ; Xu B; Lian ZX
Front Immunol; 2022; 13():894919. PubMed ID: 36420264
[TBL] [Abstract][Full Text] [Related]
8. CD103
Edwards J; Wilmott JS; Madore J; Gide TN; Quek C; Tasker A; Ferguson A; Chen J; Hewavisenti R; Hersey P; Gebhardt T; Weninger W; Britton WJ; Saw RPM; Thompson JF; Menzies AM; Long GV; Scolyer RA; Palendira U
Clin Cancer Res; 2018 Jul; 24(13):3036-3045. PubMed ID: 29599411
[No Abstract] [Full Text] [Related]
9. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
10. Nodular primary cutaneous melanoma is associated with PD-L1 expression.
Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Rodig S; Mihm M; Festa Neto C; Duncan LM; Kalil J
Eur J Dermatol; 2020 Aug; 30(4):352-357. PubMed ID: 32969795
[TBL] [Abstract][Full Text] [Related]
11. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.
Tarhini AA; Lee SJ; Tan AC; El Naqa IM; Stephen Hodi F; Butterfield LH; LaFramboise WA; Storkus WJ; Karunamurthy AD; Conejo-Garcia JR; Hwu P; Streicher H; Sondak VK; Kirkwood JM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074904
[TBL] [Abstract][Full Text] [Related]
12. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
13. Correlation of tumor-infiltrating immune cells of melanoma with overall survival by immunogenomic analysis.
Huang L; Chen H; Xu Y; Chen J; Liu Z; Xu Q
Cancer Med; 2020 Nov; 9(22):8444-8456. PubMed ID: 32931642
[TBL] [Abstract][Full Text] [Related]
14. Establishing standardized immune phenotyping of metastatic melanoma by digital pathology.
Sobottka B; Nowak M; Frei AL; Haberecker M; Merki S; ; Levesque MP; Dummer R; Moch H; Koelzer VH
Lab Invest; 2021 Dec; 101(12):1561-1570. PubMed ID: 34446805
[TBL] [Abstract][Full Text] [Related]
15. CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab.
Edmonds NL; Flores SE; Mahmutovic A; Young SJ; Mauldin IS; Slingluff CL
Melanoma Res; 2022 Dec; 32(6):440-450. PubMed ID: 36169985
[TBL] [Abstract][Full Text] [Related]
16. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
[TBL] [Abstract][Full Text] [Related]
17. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
[TBL] [Abstract][Full Text] [Related]
18. Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.
de Moll EH; Fu Y; Qian Y; Perkins SH; Wieder S; Gnjatic S; Remark R; Bernardo SG; Moskalenko M; Yao J; Ferringer T; Chang R; Chipuk J; Horst BA; Birge MB; Phelps RG; Saenger YM
Cancer Immunol Immunother; 2015 Sep; 64(9):1193-203. PubMed ID: 26076664
[TBL] [Abstract][Full Text] [Related]
19. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
[TBL] [Abstract][Full Text] [Related]
20. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.
Erdag G; Schaefer JT; Smolkin ME; Deacon DH; Shea SM; Dengel LT; Patterson JW; Slingluff CL
Cancer Res; 2012 Mar; 72(5):1070-80. PubMed ID: 22266112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
